Abdourahamne Diallo

Dr. Abdourahamne Diallo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
BLBenoit Lattuca
Benoit Lattuca
VSVuthy Sy
Vuthy Sy
LNLee Nguyen
Lee Nguyen
MBMaguy Bernard
Maguy Bernard
MZMichel Zeitouni
Michel Zeitouni
JSJohanne Silvain
Johanne Silvain

19 November 2024 in Circulation
Verified
Journal Article
Closed access
MHMarie Hauguel-Moreau
Marie Hauguel-Moreau
PGPaul Guedeney
Paul Guedeney
CDClaire Dauphin
Claire Dauphin
VAVincent Auffret
Vincent Auffret
JCJen-Michel Clerc
Jen-Michel Clerc
AGACTION Study Group
ACTION Study Group
BACKGROUND: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure. METHODS: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design). Patients were randomized in a 1:1:1 ratio after PFO closure to receive flecainide (150 mg once daily in a sustained-release dose) for 3 months, flecainide (150 mg once daily in a sustained-release dose) for 6 months, or no additional treatment (standard of care) for 6 months. The primary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor. The secondary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded with insertable cardiac monitor during the 3- to 6-month period after PFO closure. RESULTS: A total of 186 patients were included (mean age, 54 years; 68.8% men) and AA (≥30 seconds) occurred in 53 patients (28.5%) during the 6-month follow-up; 86.8% of these AA events occurred in the first month after PFO closure. The primary outcome occurred in 33 of 123 (26.8%) and 16 of 63 (25.4%) patients receiving flecainide for at least 3 months or standard of care, respectively (risk difference, 1.4% [95% CI, −12.9% to 13.8%]; NS). The secondary end point occurred in 3 of 60 (5.0%), 4 of 63 (6.3%), and 5 of 63 (7.9%) patients receiving flecainide for 6 months, for 3 months, or standard of care, respectively (risk difference, −2.9% [95% CI, −12.7% to 6.9%], and risk difference, −1.6% [95% CI, −11.8% to 8.6%], respectively). CONCLUSIONS: In the first 6 months after successful PFO closure, AA (≥30 seconds) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05213104.

28 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MBMehdi Benchoufi
Mehdi Benchoufi
JBJerôme Bokobza
Jerôme Bokobza
ACAnthony CHAUVIN
Anthony CHAUVIN
EDElisabeth Dion
Elisabeth Dion
MBMarie-Laure Baranne
Marie-Laure Baranne
PBPierre Bourrier
Pierre Bourrier
Background: Chest CT (CT) is the reference for assessing pulmonary injury in suspected or diagnosed COVID-19 with signs of clinical severity. We explored the role of lung ultrasonography (LU) in quickly assessing lung status in these patients. Methods: eChoVid is a multicentric study based on routinely collected data, conducted in 3 emergency units of Assistance Publique des Hôpitaux de Paris (APHP); 107 patients were included between March 19, 2020 and April 01, 2020 and underwent LU, a short clinical assessment by 2 emergency physicians blinded to each other’s and a CT. LU consisted of scoring lesions in 8 chest zones from 0 to 3, defining a severity global score (GS) ranging from 0 to 24. CT severity score ranged from 0 to 3 according to the extent of interstitial pneumonia signs. 48 patients underwent LU by both an expert and a newly trained physician. Findings: The GS showed good performance to predict CT severity assessment of COVID-19 as normal versus pathologic: AUC=0.93, maximal Youden index 1 with 95% sensitivity, and 83% specificity. Similar performance was found for CT assessment as normal or minimal versus moderate or severe (n=90): AUC 0.89, maximal Youden index 7 with 86% sensitivity, and 78% specificity. Good agreement was found for zone scoring assessed by new trainee (30mn theory + 30mn practice) and expert (n=14,14*8 checkpoints), weighted kappa 0.85-1; moderate agreement was found for new trainee (n=48, 30mn theory) and expert, kappa 0.62-0.81. Interpretation: GS score is a simple tool to assess lung damage severity in patients with suspected or diagnosed COVID-19. Comparing the performance of new trainees and expert physicians opens a path for adoption beyond the scope of experts. LU is a good candidate for patients triage, especially in case of CT availability issues.

27 January 2026 in Circulation
Verified
Journal Article
Closed access
GLGilles LEMESLE
Gilles LEMESLE
RDRomain Didier
Romain Didier
ADAbdourahamne Diallo
Abdourahamne Diallo
HDHubert Dromas
Hubert Dromas
CBChristophe Bauters
Christophe Bauters
GCGuillaume Cayla
Guillaume Cayla

28 January 2025 in Neurology
Verified
Journal Article
Closed access
FMFanny MOCHEL
Fanny MOCHEL
AMAurélie Méneret
Aurélie Méneret
IAIsaac M. Adanyeguh
Isaac M. Adanyeguh
CGCamille Giron
Camille Giron
EHElodie Hainque
Elodie Hainque
ADAlexandra Durr
Alexandra Durr
Brain energy deficiency occurs at the early stage of Huntington disease (HD). Triheptanoin, a drug that targets the Krebs cycle, can restore a normal brain energetic profile in patients with HD. In this study, we aimed at assessing its efficacy on clinical and neuroimaging structural measures in HD. We conducted a 6-month bicentric (Paris, Leiden) double-blind randomized controlled trial followed by a 6-month open-label phase, between June 2015 and December 2019. We enrolled 107 patients at the early stage of HD-total motor score (TMS) of the UHDRS between 5 and 40. Participants received triheptanoin 1 g/kg/day or placebo (ratio 1/1). The primary outcome was the rate of caudate atrophy at 6 months using the caudate boundary shift integral (cBSI) method. Main secondary outcomes were cBSI at 12 months, TMS, and diffusion imaging at 6 and 12 months. Analysis was conducted using ANOVA, and data were presented with a 95% CI. To perform a 12-month comparison, we used the placebo arm of a 12-month randomized controlled trial conducted in parallel, using the double robust propensity score method. One hundred patients were randomized (mean age 49 years, 52% women). Fourteen patients withdrew from the study, including 10 because of gastrointestinal effects. There was no difference in cBSI at 6 months between groups (mean 0.026 [0.018-0.033] vs 0.023 [0.014-0.032]). TMS at 12 months was stable in patients treated with triheptanoin for 12 months (mean 0.6 [-1.1 to 2.1]), whereas it increased in patients initially on placebo (2.5 [1.2-3.8]). Compared with the external placebo control group, caudate atrophy decreased by approximately 50% (0.038 [0.028-0.048] vs 0.070 [0.057-0.082]) and TMS stabilized (0.66 [-1.07 to 2.48] vs 2.65 [1.38-3.89]) in patients treated with triheptanoin for 12 months. There was no effect of triheptanoin on caudate atrophy over 6 months. Compared with the external placebo group, triheptanoin was associated with motor stability and decreased caudate atrophy in patients treated for 12 months, but the post hoc nature of these findings is a major limitation. clinicaltrials.gov NCT02453061, May 25, 2015. First patient enrolled on June 29, 2015. This study provides Class I evidence that triheptanoin does not slow caudate atrophy compared with placebo over 6 months in patients with early HD.

28 May 2021 in Medicine
Verified
Journal Article
Open access
RBRuxandra Burlacu
Ruxandra Burlacu
JLJonathan London
Jonathan London
AFAudrey Fleury
Audrey Fleury
TSThomas Sené
Thomas Sené
ADAbdourahamne Diallo
Abdourahamne Diallo
DSDamien Sène
Damien Sène
To assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC were matched for baseline epidemiological and clinical features and compared to 27 severe COVID-19 patients treated with SOC alone. Baseline characteristics of the study population were comparable between groups. Eleven patients (20%) died. TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%), despite a higher decrease of the C-reactive protein at Day 7 (10.7 vs 52 mg/L; P < 10−3). Compared to the 43 patients alive at the end-of follow-up, patients who died were older (78 vs 64 years; P < 10−3), with 82% of them older than 72 years vs only 23% of live patients (P < 10−3). Age (OR = 1.15; 95%CI = 1.04–1.3; P = .008) and age over 72 years (OR) = 14.85; 95%CI = 2.7–80; P = .002) were independently associated with mortality. TCZ in addition to SOC for severe COVID-19 patients did not reduce mortality, subsequent need for invasive mechanical ventilation nor did it shorten the time of oxygen support, despite better control of the inflammatory response. More powerful and randomized controlled trials are warranted to determine if TCZ is effective in the management of COVID-19.